Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;151(1):127-138.
doi: 10.1016/j.chest.2016.08.1462. Epub 2016 Sep 13.

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review

Bethany T Samuelson  1 , Adam Cuker  2 , Deborah M Siegal  3 , Mark Crowther  3 , David A Garcia  4
Affiliations

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review

Bethany T Samuelson et al. Chest. 2017 Jan.

Abstract

Background: Direct oral anticoagulants (DOACs) are the treatment of choice for most patients with atrial fibrillation and/or noncancer-associated venous thromboembolic disease. Although routine monitoring of these agents is not required, assessment of anticoagulant effect may be desirable in special situations. The objective of this review was to summarize systematically evidence regarding laboratory assessment of the anticoagulant effects of dabigatran, rivaroxaban, apixaban, and edoxaban.

Methods: PubMed, Embase, and Web of Science were searched for studies reporting relationships between drug levels and coagulation assay results.

Results: We identified 109 eligible studies: 35 for dabigatran, 50 for rivaroxaban, 11 for apixaban, and 13 for edoxaban. The performance of standard anticoagulation tests varied across DOACs and reagents; most assays, showed insufficient correlation to provide a reliable assessment of DOAC effects. Dilute thrombin time (TT) assays demonstrated linear correlation (r2 = 0.67-0.99) across a range of expected concentrations of dabigatran, as did ecarin-based assays. Calibrated anti-Xa assays demonstrated linear correlation (r2 = 0.78-1.00) across a wide range of concentrations for rivaroxaban, apixaban, and edoxaban.

Conclusions: An ideal test, offering both accuracy and precision for measurement of any DOAC is not widely available. We recommend a dilute TT or ecarin-based assay for assessment of the anticoagulant effect of dabigatran and anti-Xa assays with drug-specific calibrators for direct Xa inhibitors. In the absence of these tests, TT or APTT is recommended over PT/INR for assessment of dabigatran, and PT/INR is recommended over APTT for detection of factor Xa inhibitors. Time since last dose, the presence or absence of drug interactions, and renal and hepatic function should impact clinical estimates of anticoagulant effect in a patient for whom laboratory test results are not available.

Keywords: antithrombotic therapy; deep venous thrombosis; direct oral anticoagulants; laboratory; pulmonary embolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
This Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram illustrates dabigatran, rivaroxaban, apixaban, and rivaroxaban literature searches.
See this image and copyright information in PMC

References

    1. Kearon C., Akl E.A., Comerota A.J., and the American College of Chest Physicians Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed—American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e419S–e494S. - PMC - PubMed
    1. Ansell J.E. Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2016;41(1):1–2. - PMC - PubMed
    1. January C.T., Wann L.S., Alpert J.S. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–e267. - PMC - PubMed
    1. Connolly S.J., Ezekowitz M.D., Yusuf S. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. - PubMed
    1. Granger C.B., Alexander J.H., McMurray J.J. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. - PubMed

Publication types

MeSH terms